Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Philogen S.p.A. clinical trials
Part of Nerbio S.r.l., which holds 53.35% of voting rights as of 2025-12-31. Source
The registry lists 49 studies whose lead sponsor is Philogen S.p.A.. 17 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.
Keep track of what changes. Save the Philogen S.p.A. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Philogen S.p.A..
- Philogen S.p.A.49 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 49 of 49.
- A Study of F8IL10 Intra-articular Treatment in Rheumatoid ArthritisRecruitingNCT07245992Phase 1
- Safety and Early Signs of Efficacy of IL12-L19L19.RecruitingNCT04471987Phase 1
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsRecruitingNCT06284590Phase 2
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)RecruitingNCT07227350Phase 2
- L19IL2/L19TNF in Patients With Cutaneous Squamous Cell CarcinomaRecruitingNCT07228442Phase 2
- L19IL2/TNF in Patients With Basal Cell CarcinomaRecruitingNCT07227870Phase 2
- A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate CancerRecruitingNCT07600554Phase 1
- A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid TumorsNot yet recruitingNCT07566897Phase 1
- A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid TumorsRecruitingNCT06640413Phase 1
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma PatientsRecruitingNCT03567889Phase 3
- A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or OligodendrogliomaNot yet recruitingNCT07120984Phase 2
- A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First ProgressionRecruitingNCT04573192Phase 1/2
- A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue SarcomaRecruitingNCT04650984Phase 3
- Intratumoral Administration of Daromun in Non-melanoma Skin Cancer PatientsRecruitingNCT04362722Phase 2
- Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaRecruitingNCT04443010Phase 1/2
- Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)RecruitingNCT03420014Phase 2
- L19IL2/L19TNF in Skin Cancer PatientsRecruitingNCT05329792Phase 2
- A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceActive, not recruitingNCT06336291Phase 2
- A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive CancerCompletedNCT06840548Phase 1
- A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate CancerCompletedNCT06840535Phase 1
- Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular TreatmentWithdrawnNCT05622175Phase 1
- Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue SarcomaActive, not recruitingNCT04733183Phase 2
- A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid TumorsCompletedNCT05784597Phase 1
- Neoadjuvant L19IL2/L19TNF- Pivotal StudyActive, not recruitingNCT02938299Phase 3
- Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First ProgressionWithdrawnNCT05304663Phase 1
- Dose Finding Study of L19TNF and Doxorubicin in Patients With STSActive, not recruitingNCT04032964Phase 1
- A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT02957019Phase 1/2
- A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT02957032Phase 1
- Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First RelapseCompletedNCT03779230Phase 1/2
- A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTXTerminatedNCT02270632Phase 2
- F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung CancerStatus unknownNCT05468294Phase 1/2
- Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT03207191Phase 1
- Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour PatientsCompletedNCT01134250Phase 1/2
- Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer PatientsTerminatedNCT01198522Phase 1
- Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV MelanomaCompletedNCT01213732Phase 1
- A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic MelanomaStatus unknownNCT02076646Phase 1/2
- L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid TumoursCompletedNCT02076620Phase 1
- F16IL2 Plus Paclitaxel in Metastatic Merkel Cell CarcinomaTerminatedNCT02054884Phase 2
- Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis PatientsCompletedNCT02076659Phase 1
- Intratumoral Administration of L19IL2/L19TNFCompletedNCT02076633Phase 2
- Intratumoral Application of L19IL2 in Patients With Malignant MelanomaCompletedNCT01253096Phase 2
- A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With CancerCompletedNCT01240720Phase 1/2
- Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic MelanomaTerminatedNCT01055522Phase 2
- Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour PatientsTerminatedNCT01131364Phase 1/2
- A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid TumoursCompletedNCT01058538Phase 1/2
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid TumorsCompletedNCT01125085Phase 2
- 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)TerminatedNCT01124812Phase 1
- Radioimmunotherapy With 131I-L19SIP in Patients With CancerTerminatedNCT01242943Phase 1/2
- L19TNFα in Patients With Advanced Solid TumorsCompletedNCT01253837Phase 1/2